Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 778 of 6351
-
New drug targets Hard-to-Treat cancers with PI3K mutation
Disease control OngoingOKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) wil…
Phase 1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Rowing to recovery: can a simple exercise mend hearts damaged by chemotherapy?
Disease control Recruiting nowThere are more than 3.8 million breast cancer survivors in the United States and cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidenc…
Sponsor: University of Florida • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for advanced anal cancer: chemo before radiation may boost survival
Disease control Recruiting nowSquamous cell carcinoma of the anus is still a rare disease but its incidence increases mostly due to its association with human papillomavirus (HPV). When localized, the standard treatment combines radiotherapy and chemotherapy with 5FU and mitomycin-C. Chemoradiotherapy (CRT) a…
Phase 3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 26, 2026 12:50 UTC
-
AI-Powered nudges aim to get millions moving
Prevention CompletedTo evaluate the impact of two personalized nudging strategies delivered as pop-up notifications via the Fitbit app on user step count. Specifically, to personalize the following parameters of the pop-up notification system: message content, and timing (hr of the day).
Sponsor: Fitbit LLC • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
New pill could stop swelling attacks in hereditary angioedema
Disease control CompletedThis is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryn…
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Engineered immune cells take on advanced kidney cancer in new trial
Disease control OngoingThis is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Phase 1/2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a kidney drug for type 2 diabetes also help type 1 patients?
Disease control CompletedResearchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes. In people with type 1 diabetes, the body does not make enough of a hormone called insulin, resulting …
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a blood transfusion save kids with severe malaria?
Disease control Recruiting nowOpen-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to boost immune attack on HPV throat cancer before surgery
Disease control OngoingThe majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, r…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a smartphone app prevent suicide? new trial tests jaspr in the ER
Symptom relief Recruiting nowThis Study will comprehensively evaluate a multi-component suicide prevention technology (Jaspr Health) that facilitates delivery of suicided-related evidence-based practices (EBPs) while replacing wasted waiting time with productive time in the Emergency Departments (EDs). The E…
Sponsor: University of Massachusetts, Worcester • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Immunotherapy combo shows promise in shrinking lung tumors before surgery
Disease control OngoingThe purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidatio…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Foam plug could open door to lung valve therapy for thousands
Disease control Recruiting nowThis is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo instillation of AeriSeal Foam in the target lobe and subsequent assessment of CV…
Sponsor: Pulmonx Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing soli…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for duchenne: experimental drug targets genetic glitch
Disease control Recruiting nowThis is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered o…
Phase 2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New diabetes drug retatrutide takes on semaglutide in major trial
Disease control OngoingThe purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New lung cancer drug shows promise in phase 3 trial
Disease control OngoingThis clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based ch…
Phase 3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new inhaler match symbicort for asthma control?
Disease control CompletedThe goal of this clinical trial is to evaluate whether budesonide/formoterol powder for inhalation (II) manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd. is non-inferior to the active comparator, Symbicort® Turbuhaler® (AstraZeneca), in the treatment of adult bronchia…
Phase 3 • Sponsor: Shanghai Xin Huanghe Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New triple inhaler aims to cut heart and lung emergencies in COPD
Disease control Recruiting nowThis study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New light therapy targets deadly brain tumors during surgery
Disease control OngoingThe primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma. This treat…
Phase 1/2 • Sponsor: Hemerion Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC